Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy : Review of current strategies
© 2017 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd..
A large number of patients with type 2 diabetes (T2D) on basal insulin do not reach their HbA1c goals and require additional therapy to address postprandial hyperglycemia. Guidelines from expert bodies have outlined several approaches to accomplish postprandial glucose (PPG) control, and recent literature suggests several more. This article provides strategies for primary care physicians caring for patients with T2D who do not achieve glycemic control with basal insulin alone. Current treatment guidelines and strategies for improving PPG control are reviewed, including the efficacy, safety, and cost-effectiveness of rapid-acting insulin (RAI) analogs, premixed insulin, glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), dipeptidyl peptidase 4 inhibitors, sodium-glucose cotransporter 2 inhibitors, and α-glucosidase inhibitors. Other approaches, such as combinations of newer basal insulin plus RAI and a fixed-ratio combination of basal insulin and a GLP-1 RA, are also described.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Journal of diabetes - 10(2018), 2 vom: 24. Feb., Seite 94-111 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Umpierrez, Guillermo E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
胰岛素 |
|---|
| Anmerkungen: |
Date Completed 14.08.2018 Date Revised 30.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/1753-0407.12576 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM272615587 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM272615587 | ||
| 003 | DE-627 | ||
| 005 | 20231224235241.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/1753-0407.12576 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0908.xml |
| 035 | |a (DE-627)NLM272615587 | ||
| 035 | |a (NLM)28581207 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Umpierrez, Guillermo E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy |b Review of current strategies |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.08.2018 | ||
| 500 | |a Date Revised 30.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2017 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd. | ||
| 520 | |a A large number of patients with type 2 diabetes (T2D) on basal insulin do not reach their HbA1c goals and require additional therapy to address postprandial hyperglycemia. Guidelines from expert bodies have outlined several approaches to accomplish postprandial glucose (PPG) control, and recent literature suggests several more. This article provides strategies for primary care physicians caring for patients with T2D who do not achieve glycemic control with basal insulin alone. Current treatment guidelines and strategies for improving PPG control are reviewed, including the efficacy, safety, and cost-effectiveness of rapid-acting insulin (RAI) analogs, premixed insulin, glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), dipeptidyl peptidase 4 inhibitors, sodium-glucose cotransporter 2 inhibitors, and α-glucosidase inhibitors. Other approaches, such as combinations of newer basal insulin plus RAI and a fixed-ratio combination of basal insulin and a GLP-1 RA, are also described | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a 2型糖尿病 | |
| 650 | 4 | |a diabetes mellitus type 2 | |
| 650 | 4 | |a glucagon-like peptide-1 | |
| 650 | 4 | |a insulin | |
| 650 | 4 | |a postprandial hyperglycemia | |
| 650 | 4 | |a 胰岛素 | |
| 650 | 4 | |a 胰高血糖素样肽-1 | |
| 650 | 4 | |a 餐后高血糖 | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Insulin, Short-Acting |2 NLM | |
| 700 | 1 | |a Bailey, Timothy S |e verfasserin |4 aut | |
| 700 | 1 | |a Carcia, Danielle |e verfasserin |4 aut | |
| 700 | 1 | |a Shaefer, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Shubrook, Jay H |e verfasserin |4 aut | |
| 700 | 1 | |a Skolnik, Neil |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of diabetes |d 2009 |g 10(2018), 2 vom: 24. Feb., Seite 94-111 |w (DE-627)NLM200002139 |x 1753-0407 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2018 |g number:2 |g day:24 |g month:02 |g pages:94-111 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/1753-0407.12576 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2018 |e 2 |b 24 |c 02 |h 94-111 | ||